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Abstract
Background—Appropriate utilization of acute reperfusion therapy is not a national performance
measure for ST-elevation myocardial infarction at this time, and the extent of its contemporary use
among ideal patients is unknown.
Methods—From the National Registry of Myocardial Infarction, we identified 238,291 patients
enrolled from June 1994 to May 2003 who were ideally suited for acute reperfusion therapy with
fibrinolytic therapy or primary percutaneous coronary intervention. We determined rates of not
receiving therapy across 3 time periods (June 1994–May 1997, June 1997–May 2000, June 2000–
May 2003) and evaluated factors associated with underutilization.
Results—The proportion of ideal patients not receiving acute reperfusion therapy decreased by
one-half throughout the past decade (time period 1: 20.6%; time period 2: 11.4%; time period 3:
11.6%; P<0.001). Utilization remained significantly lower in key subgroups in the most recent time
period: those without chest pain (OR, 0.29; 95% CI, 0.27–0.32); those presenting 6 to 12 hours after
symptom onset (OR, 0.57; 95% CI, 0.52–0.61); those 75 years or older (OR, 0.63 compared with
patients <55 years old; 95% CI, 0.58–0.68); women (OR, 0.88; 95% CI, 0.84–0.93); and non-whites
(OR, 0.90; 95% CI, 0.83–0.97).
Conclusions—Utilization of acute reperfusion therapy in ideal patients has improved over the last
decade, but more than 10% remain untreated. Measuring and improving its use in this cohort
represents an important opportunity to improve care.
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Introduction
In the U.S., recent quality improvement efforts for patients with ST-elevation myocardial
infarction (STEMI) have focused primarily on measuring the timely delivery of acute
reperfusion therapy.1, 2 Although shorter times-to-reperfusion are associated with better
outcomes,3 the use of measures that focus on time alone fails to capture the degree to which
acute reperfusion therapy is appropriately administered to all eligible patients. Earlier studies
from the 1990s noted that approximately 25–40% of STEMI patients did not receive acute
reperfusion therapy despite considerable evidence that its use lowers mortality.4–7 Although
substantial improvements may have occurred in the intervening decade, recent data on its use
in the U.S. are limited. If potential gaps in the use of acute reperfusion therapy are still present
– particularly in high-risk patients who are otherwise eligible – this would argue for renewed
efforts to measure and improve its utilization.
Accordingly, we assessed the contemporary use of acute reperfusion therapy in an ‘ideal’
cohort of patients using the National Registry of Myocardial Infarction (NRMI), a longstanding
U.S. registry. To identify a population with the clearest indications for acute reperfusion
therapy and one that will most likely reflect the target of national quality improvement efforts,
our focus on ideal patients was intentionally selective. NRMI was designed in part to address
this specific issue, containing detailed clinical information about indications and
contraindications for acute reperfusion therapy, including patient refusal. In addition to
examining overall trends, we specifically assessed use in several high-risk subgroups.4
Recognizing gaps in the actual receipt of acute reperfusion therapy among ideal patients has
broad implications for patient care and future quality improvement efforts that currently
overlook this important measure.
Methods
Study population
We used data in the NRMI-2, -3, and -4 cohorts collected from June 1994–May 2003. NRMI
is an ongoing registry of patients with acute myocardial infarction admitted to participating
hospitals in the U.S., and details of NRMI hospitals, cohorts and data collection have been
described elsewhere.8 Briefly, the NRMI protocol specifies that all consecutive patients with
the diagnosis of acute myocardial infarction are enrolled at participating hospitals. Cases are
typically screened using the International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) discharge diagnosis code of 410.X1. Myocardial infarction is then
confirmed based on a suggestive patient history and 1 or more of the following criteria: 1)
cardiac biomarker (e.g., creatine kinase MB or troponin) elevation; 2) electrocardiographic
evidence; and 3) scintigraphic, echocardiographic or autopsy evidence. The validity of NRMI
data has been established through a comparison with the Cooperative Cardiovascular Project.
8 Institutional review board approval is obtained at participating centers as required by the
hospital.
To construct a cohort of eligible patients ‘ideally’ suited for acute reperfusion therapy, we
limited our analysis to non-transfer-in patients with: 1) symptoms of STEMI within 12 hours
of presentation, 2) associated ST-elevation in 2 or more contiguous leads, and 3) no
contraindications to either fibrinolytic therapy or percutaneous coronary intervention (PCI). A
list of the contraindications to acute reperfusion therapy and the distribution of the population
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excluded for these reasons is listed in the Appendix. To focus on those patients with the clearest
indications for acute reperfusion therapy, we excluded patients with left-bundle branch block
pattern on their electrocardiogram, given the possibility that treatment was appropriately
withheld. We also excluded those: 1) who did not receive acute reperfusion therapy with brief
hospitalizations (<2 hours) due to death or emergent transfer because of insufficient time for
treatment and 2) with any missing data elements. We also excluded cases where acute
reperfusion therapy was withheld due to patient or family refusal; quality of life decision; and
an unclear clinical diagnosis of STEMI. Figure 1 shows the sample selection process and
specific exclusion criteria used to identify the final study population.
Outcome measures and data
The primary outcome assessed was whether a patient received acute reperfusion therapy with
either fibrinolytic therapy or primary PCI. The key independent variables represented 3 time
periods based on the date of hospital arrival: June 1994–May 1997 (time period 1), June 1997–
May 2000 (time period 2), and June 2000–May 2003 (time period 3). We chose these 3 time
periods to create an even distribution of patients and to ensure uniform data collection methods
across the study period.
Patient-level characteristics that were also included in this analysis were: demographics (age
[<55, 55–64, 65–74, >75], gender, race [white, non-white], insurance status [private, Medicare,
other]; cardiovascular risk factors [smoking, hypertension, dyslipidemia, diabetes mellitus,
family history of premature coronary artery disease]; prior coronary artery disease (prior
angina, myocardial infarction, PCI, or coronary artery bypass grafting); prior congestive heart
failure; prior stroke; presenting clinical variables (presence of chest pain, delayed presentation
[>6–12 hours after symptom onset], systolic blood pressure [<90, >180], pulse [<50, >100],
Killip classification [rales, pulmonary edema, cardiogenic shock], admission during off-hours
[weekends and 7PM-7AM weekdays]); and electrocardiographic findings (anterior STEMI,
number of leads involved). Hospital-level characteristics included type of ownership, teaching
status, urban or rural location, U.S. Census region, and the availability of onsite cardiac surgery.
Statistical analysis
We performed univariate analyses to evaluate differences in baseline patient characteristics
across the 3 time periods, with analysis of variance tests used for continuous variables and chi-
squared tests used for categorical variables. We used multivariable logistic regression to
determine the likelihood of receiving acute reperfusion therapy across the 3 time periods after
adjusting for baseline differences in patient- and hospital-level characteristics. We calculated
rates of not receiving acute reperfusion therapy by time period in the overall study population
and key patient subgroups including those without chest pain or delayed presentation, those
aged >75 years, women, and non-whites.4 To ensure that our results were not biased by
differential hospital enrollment over the study period, we repeated the analysis only using
patients at hospitals that enrolled during all 3 study periods (n=188,333) and showed similar
results in general.
We also used multivariable logistic regression to identify patient-level characteristics
associated with receiving acute reperfusion therapy in the cohort enrolled from June 2000 to
May 2003 (i.e., time period 3). All models used generalized estimating equations (GEE) to
account for clustering of patients at the hospital level. A P-value <0.05 was considered
statistically significant. We report odds ratios for all associations from the multivariable models
including their 95% confidence intervals. Statistical analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC).
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Between June 1994 and May 2003, we identified 238,291 patients with STEMI who met our
inclusion criteria and were ideally suited for acute reperfusion therapy. Overall, the mean age
of these patients was 62.6 (±13.3) while 74,571 (31.3%) were women and 32,904 (14.0%) were
non-white. Additional patient characteristics are displayed in Table 1. Due to the large size of
the data set, statistically significant differences were found across the 3 time periods for several
patient characteristics; however, for many variables absolute differences were small and not
clinically significant. The proportion of patients with prior PCI increased from 7.8% to 12.1%
during the study period, while the proportion of patients with Killip classification II, III, or IV
decreased from 15.0% to 10.4%. The proportion of patients admitted at hospitals with on-site
cardiac surgery increased from 46.8% to 56.5%.
During the study period, 34,701 (14.6%) patients ideally suited for acute reperfusion therapy
did not receive either fibrinolytic therapy or primary PCI. The proportion of patients who did
not receive acute reperfusion therapy decreased significantly between time periods 1 and 2 but
remained stable between time periods 2 and 3 (20.6% in time period 1 to 11.4% in time period
2 to 11.6% in time period 3; P <0.001 across all 3 time periods). This pattern of decline in the
proportion of patients who did not receive acute reperfusion therapy remained after adjusting
for baseline differences in patient and hospital characteristics across the 3 study periods (Figure
2). Similarly, in the key subgroups evaluated, the proportion of patients who did not receive
acute reperfusion therapy decreased throughout the study period, although utilization in these
patients remained generally lower than in the overall cohort (Figure 3).
Table 2 displays the patient characteristics independently associated with use of acute
reperfusion therapy in the most recent time period between June 2000 and May 2003. In these
patients, we identified several subgroups that were significantly less likely to receive acute
reperfusion therapy including: those with advanced age (odds ratio [OR] for patients aged ≥75
years compared with patients aged <55 years, 0.63; 95% confidence interval (CI) 0.58–0.68);
women (OR, 0.88; 95% CI, 0.84–0.93); non-whites (OR, 0.90; 95% CI, 0.83–0.97); those
without chest pain (OR, 0.29; 95% CI, 0.27–0.32); and those presenting 6 to 12 hours after
symptom onset (OR, 0.57; 95% CI, 0.52–0.61). We also found less utilization associated with
co-morbidities like prior bypass surgery (OR, 0.67; 95% CI, 0.62–0.74), heart failure (OR,
0.69; 95% CI, 0.63–0.77) and angina (OR, 0.82; 95% CI, 0.75–0.90) as well as diabetes mellitus
(OR, 0.87; 95% CI, 0.82–0.92) and hypertension (OR, 0.92; 95% CI, 0.87–0.97).
Discussion
We found substantial improvement in the use of acute reperfusion therapy among ideal patients
with STEMI between 1994 and 2003 in the U.S. Most of this improvement appeared to occur
during the late 1990s and has leveled off over recent years. It could be that a ‘ceiling’ effect
has been reached, since an expectation of perfect utilization (i.e., 100%) may be unrealistic
even in patients without identifiable contraindications. However, it is concerning that we found
substantial and persistent gaps in utilization for several key subgroups such as those without
chest pain or with delayed presentations, the very elderly, women, and minorities. Patients with
co-morbidities such as prior bypass surgery, heart failure or angina as well as diabetes mellitus
and hypertension were also less likely to receive acute reperfusion therapy. The disparities in
utilization across these groups of patients who are either at high-risk for complications
following STEMI (e.g., the elderly) or less likely to receive reperfusion therapy (e.g., women)
suggest that there is still substantial room for improving use of this life-saving therapy.
Recently time-to-reperfusion has received much attention as an important quality standard for
assessing care in STEMI patients.1, 2 While important, time-to-reperfusion does not assess the
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appropriate use of acute reperfusion therapy in eligible patients, and current measures from the
Joint Commission on Accreditation of Healthcare Organizations and the Centers for Medicare
& Medicaid Services do not consider it in their overall evaluations of hospital quality.1, 2 A
recent statement by the American College of Cardiology (ACC)/American Heart Association
(AHA) on performance measures for STEMI and non-STEMI patients recognizes the potential
limitation of excluding the use of reperfusion in national quality improvement efforts, and
recommends including such a measure in the future.9
Our findings support the incorporation of a measure of reperfusion use into national quality
improvement efforts for STEMI patients. Approximately 10% of patients who appear
otherwise ideally suited for acute reperfusion therapy do not receive it. Improving this figure
could lead to substantial improvements in mortality especially when compared with other
interventions proposed for STEMI patients. For example, the use of fibrinolytic therapy is
associated with absolute mortality reductions of 30 per 1000 treated in patients presenting
within 6 hours of symptom onset and 20 per 1000 treated in those presenting 6 to 12 hours
after symptom onset.10 In contrast, improving time-to-reperfusion by 3 to 6 hours in patients
presenting late after symptom onset is associated with an absolute mortality reduction of 11
per 1000.11 Shifting patients from fibrinolytic therapy to primary PCI may be associated with
absolute mortality reductions of 12 to 20 per 1000 patients treated if performed in a timely
manner.12, 13
Including measures of the use of acute reperfusion therapy in assessments of hospital quality
will also help to highlight persistent disparities in its utilization in high-risk subgroups. We
noted that patients without chest pain or those with delayed presentation continue to have a
much lower likelihood of receiving acute reperfusion therapy. Similarly, we found lower
utilization of acute reperfusion therapy among very elderly patients, women, and non-whites
as well as those with co-morbidities such as prior bypass surgery, heart failure and angina. For
the most part, these discrepancies were present to a comparable degree in earlier analyses from
NRMI and others.4, 14–17 Thus, while absolute rates of utilization of acute reperfusion therapy
in high-risk subgroups generally have improved over time, relative differences remain.4
There are a number of factors that may contribute to underutilization of acute reperfusion
therapy particularly in high-risk subgroups that are otherwise ideally suited for it. Previous
arguments have suggested that some clinicians may be uncomfortable with its use in certain
patients due to perceptions of less benefit or greater risk, contributing to underutilization.18,
19 This is a possible explanation for its low use in patients without chest pain or even those
with delayed presentation, although it contradicts available clinical evidence.10, 19–21 In
addition, this argument fails to explain its underutilization in groups like the very elderly,
women and non-whites.
Despite considerable debate, reasons for lower use of treatment in these patients are unknown
and clearly not endorsed by current guidelines.22 Many of these groups have been shown to
receive less aggressive therapy in other settings, such as those providing invasive
cardiovascular procedures, with possible explanations including differences in eligibility or
other clinical factors.16 However, our analyses demonstrated persistent disparities even after
multivariable adjustment. In the very elderly, another possibility for underutilization is concern
about overall frailty and the higher likelihood for complications even though these higher risk
patients may benefit more from acute reperfusion therapy.19, 23, 24 Such a “risk-treatment”
paradox has been described recently regarding heart failure and dyslipidemia.25, 26 This may
also explain its lower use in patients with pre-existing conditions including heart failure, prior
myocardial infarction, diabetes mellitus, and hypertension.27
Nallamothu et al. Page 5













Our analysis should be interpreted in the context of the following study design issues. First,
NRMI collects voluntarily reported data from participating hospitals. While NRMI hospitals
do include a wide variety of acute-care hospitals, these centers generally tend to be larger than
non-participating hospitals. Our results therefore may not be generalizable to all U.S. hospitals.
Second, this was an observational study and there is the potential for residual confounding
despite adjustment for several patient- and hospital-level covariates. We lacked data, for
example, on some patient characteristics that may have contributed to underutilization,
including the presence of chronic renal insufficiency or socioeconomic factors.
Despite these limitations, this study has unique strengths. In particular, we were able to use the
extensive data available in NRMI to establish an ‘ideal’ cohort that was eligible for acute
reperfusion therapy. In contrast to other studies, we were able to exclude patients with non-
clinical contraindications such as patient or family refusal, or a quality of life decision. We
also excluded patients with left bundle branch block patterns, focusing on those with ST-
elevation on their presenting electrocardiograms (similar to the strategy proposed by the ACC/
AHA).9 Patients with left bundle branch block pattern remain a challenging subset in which
determining whether treatment was appropriately withheld is often difficult.28 Finally, we
excluded those patients who did not receive acute reperfusion therapy with brief
hospitalizations (<2 hours) due to death or emergent transfer because of insufficient time for
initiating treatment. As a result of these factors, our estimates of underutilization are more
conservative than those found in prior reports from NRMI and others.4–7
While utilization of acute reperfusion therapy has improved over the last decade, approximately
10% of ideal patients do not receive adequate treatment. Measuring its appropriate utilization
in this population will be important to assess hospital performance in acute myocardial
infarction and possibly improve quality of care. In particular, it may be valuable for quality
efforts to focus on high-risk subgroups such as those without chest pain or with delayed
presentation that continue to have significantly lower rates of utilization. Recent
recommendations by the ACC/AHA Task Force on Performance Measures have also endorsed
incorporating a measure of reperfusion use into national quality improvement efforts for
STEMI patients and are supported by our findings.
Clinical significance
• While use of acute reperfusion therapy has improved over the last decade, more than
10% of eligible patients with STEMI still do not receive it.
• Substantial gaps in utilization are most prominent in high-risk groups like STEMI
patients without chest pain or with delayed presentations, the very elderly, women
and minorities.
• Improving use of acute reperfusion therapy could lead to substantial improvements
in mortality compared with other interventions proposed for STEMI patients.
• National quality improvement efforts should consider incorporating a measure of
reperfusion use for assessing hospital performance in acute myocardial infarction.
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Appendix. Distribution of contraindications to reperfusion therapy in overall
cohort
Contraindication No. of patients
Active internal bleeding or known bleeding diathesis 5,173
History of stroke 5,662
History of intracranial neoplasm, AVM or aneurysm 392
Recent surgery or trauma 3,939
Severe uncontrolled hypertension 1,297
Traumatic cardiopulmonary resuscitation 2,944
Patient or family refusal 2,826
Refusal due to quality of life decision 5,025
An unclear clinical diagnosis of STEMI 5,493
Other or not clearly specified 9,709
Total 35,412*
*
Total is less than the sum of the individual components due to overlap AVM, arteriovenous malformation; STEMI, ST-elevation myocardial infarction
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Flow diagram displaying criteria for selection of study population
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Unadjusted and adjusted rates of receiving reperfusion therapy in patients with STEMI
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Adjusted rates of receiving reperfusion therapy in key patient subgroups
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